Welcome!

News Feed Item

Bladder Cancer: So Much Cost, Such Little Progress

LONDON, March 20, 2014 /PRNewswire/ --



The alarming truth about the huge financial and personal impact of bladder cancer is highlighted in a new paper published in European  Urology[1]. The UK charity, Action on Bladder Cancer, co-authors an editorial[2] on the paper, drawing attention to the urgent need to address the enormous, yet largely ignored, burden that this distressing disease places on individuals and society.

     (Logo: http://photos.prnewswire.com/prnh/20130507/613105 )

Bladder cancer has the highest lifetime treatment costs per patient of all cancers[3]. The direct medical costs of cancer care in the UK are £65M[4]. As the seventh most common cancer in the UK, bladder cancer accounts for 1 in 30 new cases of cancer each year[5]. Even so, outcomes for bladder cancer have changed little for three decades, despite significant improvements in the 5-year survival rates for prostate and kidney cancers during this same period[2].

Bladder cancer has a deep and devastating reach into the health of our society. Overall, deaths from the disease remain higher in England than other European countries with similar incidence rates and survival is worsening[6].  On average 14 people die each day from bladder cancer[4], and yet it is largely neglected by those who could make a difference to the lives of so many people.

The paper and editorial discuss the key issues which are creating and sustaining this unacceptable situation:

  • There are large gaps in our knowledge regarding the efficacy and cost-effectiveness of treatment approaches
  • There is a lack of research funding compared to other cancers; despite being the seventh most common cancer, bladder cancer receives just 0.6% of NCRI cancer research spending in the UK[7]
  • There is a lack of sufficient randomized controlled trials (RCTs). RCTs provide the strongest evidence on which clinicians can base their practice however only 238 RCTs were published for bladder cancer between 1995 and 2010[8].
  • There is a clear and urgent need for the development of new drugs for bladder cancer.

As a result, bladder cancer still does not have a robust evidence base to support much of what is current everyday practice. Patient pathways of care are complex and prolonged, resulting in large variations in practice worldwide. Even at the basic level of public awareness of the disease, many people have not heard of bladder cancer and do not recognise that even just one episode of visible blood in the urine may indicate that bladder cancer may be present. For many people, diagnosis is delayed or misdiagnosed resulting in worse clinical outcomes. This is clearly just not good enough.

Mr Richard T Bryan, Chief Investigator, Bladder Cancer Prognosis Programme, and Senior Research Fellow, University of Birmingham, and Action on Bladder Cancer Regional Advisor says "The review by Svatek et al demonstrates the huge costs associated with the diagnosis and management of bladder cancer, the large variations in practice worldwide, and the significant gaps in our knowledge. Our accompanying editorial expands on these themes and others; most importantly, the lack of improvement in outcomes for bladder cancer patients over the last three decades, the poor funding for bladder cancer research, and the poor awareness of bladder cancer amongst the general public and the non-urologic scientific community. We need to advance the cause for bladder cancer patients and make much more progress with this very common disease."

Bladder cancer lags starkly behind nearly all other cancers. Action needs to be taken now to improve the life expectancy of so many people with bladder cancer. Quite simply, more has to be done.

About  Action  on  Bladder  Cancer 

Action on Bladder Cancer is a UK charity working to improve public awareness, medical knowledge and the priority of bladder cancer on the UK health agenda, to ensure earlier recognition and diagnosis and so allow more effective management to improve the outcomes for people with bladder cancer. (http://www.actiononbladdercancer.org).

References:

  1. Svatek et al. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology. Published online Feb 2014. Abstract available at: http://www.europeanurology.com/article/S0302-2838(14)00018-9/abstract/the-economics-of-bladder-cancer-costs-and-considerations-of-caring-for-this-disease
  2. Bryan RT et al. So much cost, such little progress. European Urology. Published online Feb 2014.  http://www.europeanurology.com/article/S0302-2838(14)00160-2/abstract
  3. Sievert KD et al. Economic aspects of bladder cancer. What are the benefits and costs? World  J  Urol. Jun 2009; 27(3): 295-300.
  4. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14:1-iv
  5. Cancer Research UK, Cancer Stats Key Facts, Bladder Cancer http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/bladder-cancer/uk-bladder-cancer-statistics
  6. Eylert MF et al (2014). Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. Journal  of  Clinical  Urology 0(0) 1-9
  7. National Cancer Research Institute. NCRI spend by cancer site.  Available at http://www.ncri.org.uk/what-we-do/research-database
  8. Bachir, B. G., Shariat, S. F., Zlotta, A., Svatek, R., Black, P. C., Shah, J. B., Kassouf, W., Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada) (2013), Demographic analysis of randomized controlled trials in bladder cancer.  BJU  International, 111: 419-426


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...